The estimated Net Worth of Lawson Macartney is at least 4.09 百万$ dollars as of 16 May 2023. Lawson Macartney owns over 16,000 units of Viking Therapeutics Inc stock worth over 3,890,991$ and over the last 10 years he sold VKTX stock worth over 0$. In addition, he makes 196,766$ as Independent Chairman of the Board at Viking Therapeutics Inc.
Lawson has made over 4 trades of the Viking Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 16,000 units of VKTX stock worth 19,040$ on 16 May 2023.
The largest trade he's ever made was buying 47,965 units of Viking Therapeutics Inc stock on 29 May 2018 worth over 250,377$. On average, Lawson trades about 6,717 units every 121 days since 2015. As of 16 May 2023 he still owns at least 63,965 units of Viking Therapeutics Inc stock.
You can see the complete history of Lawson Macartney stock trades at the bottom of the page.
Dr. Lawson Macartney Ph.D. serves as Independent Chairman of the Board of the Company.D., is an Independent Chairman of the Board of the Company. From January 2017 to June 2017, Dr. Macartney served as CEO of Scout Bio Inc., a gene therapy company developing therapies for companion animals. Dr. Macartney serves on the Board of Dechra PLC, an international animal health pharmaceutical company based in the UK, and on the Supervisory Board of the Netherlands Translational Research Centre, a preclinical biopharmaceutical company based in The Netherlands. He served as President, Chief Executive Officer and a member of the board of directors of Ambrx Inc., a biopharmaceutical company, from February 2013 to June 2015. Prior to Ambrx, Dr. Macartney served at Shire AG, a specialty biopharmaceutical company, as Senior Vice President of the Emerging Business Unit from 2011 to 2013, where he was responsible for discovery initiatives through Phase 3 development of Shire’s Specialty Pharmaceutical portfolio. Prior to joining Shire AG, he served at GSK, a pharmaceutical company, from 1999 to 2011, serving as Senior Vice President of Global Product Strategy and Project Portfolio Management from 2007 to 2011, as Senior Vice President, Cardiovascular and Metabolic Medicine Development Center from 2004 to 2007, and as Vice President, Global Head of Cardiovascular, Metabolic and Urology Therapeutic Areas from 1999 to 2004. Prior to joining GSK, Dr. Macartney was employed at Astra Pharmaceuticals from 1998 to 1999 in leadership roles in operations, marketing and sales, and served as Executive Director, Commercial Operations at AstraMerck, Inc., a pharmaceutical company, from 1996 to 1998. Dr. Macartney received his Ph.D. from Glasgow University in Scotland in 1982, where he was a Royal Society Research Fellow, and his B.V.M.S. (equivalent to a D.V.M.) in 1979 from Glasgow University Veterinary School. He is also trained in diagnostic pathology and is a Fellow of the Royal College of Pathologists.
As the Independent Chairman of the Board of Viking Therapeutics Inc, the total compensation of Lawson Macartney at Viking Therapeutics Inc is 196,766$. There are 4 executives at Viking Therapeutics Inc getting paid more, with Brian Lian having the highest compensation of 3,512,120$.
Lawson Macartney is 62, he's been the Independent Chairman of the Board of Viking Therapeutics Inc since 2015. There are 1 older and 8 younger executives at Viking Therapeutics Inc. The oldest executive at Viking Therapeutics Inc is J. Matthew Singleton, 67, who is the Independent Director.
Lawson's mailing address filed with the SEC is C/O VIKING THERAPEUTICS, INC., 9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA, 92121.
Over the last 10 years, insiders at Viking Therapeutics Inc have traded over 46,107,976$ worth of Viking Therapeutics Inc stock and bought 199,715 units worth 855,627$ . The most active insiders traders include Brian Lian、Charles A Jr Rowland、Marianna Mancini. On average, Viking Therapeutics Inc executives and independent directors trade stock every 75 days with the average trade being worth of 4,137,170$. The most recent stock trade was executed by Brian Lian on 21 August 2024, trading 1,000 units of VKTX stock currently worth 7,770$.
Viking Therapeutics Inc executives and other stock owners filed with the SEC include: